ALTURiX Acquires UK Rights to Liothyronine

ssued: London, Monday 30^th May 2022

 

Announced today, ALTURiX - a rapidly-growing British pharmaceutical company - has acquired the exclusive rights to liothyronine for the United Kingdom following the finalisation of an agreement with HELM AG, based in Hamburg.

 

Founded in 2020 following the acquisition of two family-owned pharmaceutical companies, ALTURiX has a portfolio of well-known medicines which are prescribed widely by the NHS.  The mission set out by the ALTURiX founders is to reliably provide branded  products at an appropriate price.  ALTURiX was created and shaped to provide these high-quality medicines to the NHS with streamlined efficiency.  

 

The company portfolio includes three heritage branded products acquired from Novartis - all proven and acknowledged to improve patients’ health.  ALTURiX reliably supplies these products to the NHS and other international markets, using its manufacturing partner based in Switzerland.  This is in keeping with the company’s commitment to reliably deliver high-quality products, at a sensible price.

 

In addition, for the last five years the company has been growing rapdily through a programme of new product acquisitions, and market introductions.  

 

Commenting on the agreement, Dr Simon Clough – Founder and Director at ALTURiX said,

 

 “We are delighted to announce this deal with HELM for such an important product for UK thyroid patients – especially as this is International Thyroid Awareness Week.  The agreement for liothyronine is the latest example of our successful growth strategy, and further demonstrates the company’s commitment to reliably and affordably supply important products like this, to increase the currently-limited options available to patients and the NHS.”  

 

 

                                                

                                                     - Ends -

 

 

About ALTURiX

 

Headquartered in Milton Keynes, ALTURiX can trace its origins back to 1998 when the rights for its three heritage products – Phosphate Sandoz^TM, Sando-K®, and Slow Sodium® – were acquired from Novartis.  These products have since been reliably supplied to the NHS, helping to improve patients’ health.

 

The company’s stated aim is to provide high-quality medicines at appropriate prices in markets where current prescriber and patient choices are limited, and to thereby develop a reputation for reliability, and delivery of value.  

 

 

Company Contacts:    Lak Sahota

                                    Founder and Director

                                    Email: lak.sahota@alturix.com

 

                                    Simon Fisher

                                    Founder and Director

                                    Email: simon.fisher@alturix.com

 

Company Address:      287 Upper Fourth Street

                                    Milton Keynes

                                    MK9 1EH

                                    United Kingdom

 

Telephone:                  +44 (0)1908 038083

 

Website:                      www.alturix.com

 

Email:                          info@alturix.com